Theorem Clinical Research and Gallus BioPharmaceuticals have announced an exclusive partnership to accelerate research, development and manufacturing of biopharmaceuticals.
As a part of the collaboration, Gallus will provide process development and clinical and commercial supply for mammalian cell-based biopharmaceutical products to Theorem’s customers.
Theorem will provide contract research services to Gallus’ customers to increase both companies’ global reach and accelerate their customers’ products through the clinic to market.
Gallus president and CEO Mark Bamforth said that Gallus’ mission is to meet the biopharmaceutical supply needs of customers through a premier manufacturing operation, leveraging the organization’s deep experience in development and manufacturing with an entrepreneurial, innovative, customer focus.
"With our new collaboration with Theorem, we’ll be able to expand our portfolio of high quality services to meet more of the comprehensive demands of our customers," Bamforth added.
Theorem chief executive officer John Potthoff said that according to Potthoff, Theorem’s partnership with Gallus will ensure that Theorem’s customers receive top-notch service and have access to everything they need to advance their trials and prepare for submission success with superior clinical and commercial supply.